Skip to main content

Table 1 Demographic characteristics of participants

From: Growth associated protein 43 (GAP-43) predicts brain amyloidosis in Alzheimer’s dementia continuum: an [18 F] AV-45 study

 

CN

(n = 77)

MCI

(n = 111)

AD

(n = 38)

Comparison

P value*

P value

Age (years)

71.9 ± 6.7

70.6 ± 7.6

73.1 ± 6.6

CN vs. MCI

0.669

0.071a

CN vs. AD

1.000

MCI vs. AD

0.193

Gender (female)

38 (49.4%)

60 (54.1%)

6 (16.8%)

 

0.579b

Education (years)

17.2 ± 2.2

16.1 ± 2.6

16.5 ± 2.6

CN vs. MCI

0.024

0.029c

CN vs. AD

0.544

MCI vs. AD

1.000

MMSE

29.14 ± 1.11

27.85 ± 1.88

22.11 ± 3.48

CN vs. MCI

< 0.001

< 0.001c

CN vs. AD

< 0.001

MCI vs. AD

< 0.001

ADAS-Cog 13

7.01 ± 3.36

12.44 ± 7.1

28.32 ± 10.35

CN vs. MCI

< 0.001

< 0.001c

CN vs. AD

< 0.001

MCI vs. AD

< 0.001

CDR-SB

1 ± 0.3

1.18 ± 0.92

5.01 ± 1.97

CN vs. MCI

< 0.001

< 0.001c

CN vs. AD

< 0.001

MCI vs. AD

< 0.001

CSF T-tau (pg/mL)

68.9 ± 36.5

77.4 ± 44

151.7 ± 80.6

CN vs. MCI

0.362

< 0.001c

CN vs. AD

< 0.001

MCI vs. AD

< 0.001

CSF P-tau (pg/mL)

39.4 ± 26.7

43.4 ± 24

73.6 ± 36.2

CN vs. MCI

0.559

< 0.001c

CN vs. AD

< 0.001

MCI vs. AD

< 0.001

CSF Aβ42 (pg/mL)

200.6 ± 52.4

182 ± 55.3

132.2 ± 35.2

CN vs. MCI

0.062

< 0.001c

CN vs. AD

< 0.001

MCI vs. AD

< 0.001

  1. Abbreviations: CN: cognitively normal; MCI: mild cognitive impairment; AD: Alzheimer’s disease; MMSE: Mini-Mental State Examination; CDR-SB: Clinical Dementia Rating Scale-Sum of Boxes; ADAS-Cog 13: Alzheimer’s Disease Assessment Scale-Cognitive 13; T-tau: total tau; P-tau: phosphorylated tau; Aβ: amyloid-β; CSF: cerebrospinal fluid; a ANOVA test; b Chi square test; c Kruskal-Wallis Test; * Significance values have been adjusted by the Bonferroni correction for multiple tests